Visual abstract | REACH5: Ruxolitinib in pediatric cGvHD

The GvHD Hub is pleased to present a visual abstract representing preliminary data from the phase II REACH5 trial (NCT03774082) evaluating ruxolitinib, a Janus kinase inhibitor, for use in pediatric patients with chronic graft-versus-host disease (cGvHD).¹

Occurrence of cGvHD in pediatric patients can impact quality of life and morbidity.¹ In these patients, systemic corticosteroids are the current standard-of-care treatment and there are limited options for second-line therapies.¹ In REACH5, pediatric patients with treatment-naïve or steroid-refractory cGVHD were treated with ruxolitinib plus corticosteroids. Patients were split into three groups according to age:

• Group 1: ≥12yrs – <18yrs
• Group 2: ≥6yrs – <12yrs
• Group 3: ≥2yrs – <6yrs

The majority of patients in all groups were male. At the data cutoff, 27.3%, 31.3%, and 57.1% of patients in Groups 1, 2, and 3 were ongoing in the treatment phase, respectively. While on treatment or within 30 days of the last dose, 27.3%, 18.8%, and 14.3% of patients in Groups 1, 2, and 3 had died, respectively.¹

The safety profile of ruxolitinib in this study was similar to previous studies in pediatric patients, with ruxolitinib treatment leading to high overall response rates across all age groups.¹